Date:	4/11/2023
Your Name:	Dr. Adi Kashi
Manuscript Title:	Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis of Redaction Rates and the Anticipated RAPTURE
Manuscript Number (if known):	BMJ-2023-077329

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			entities with whom you have this nip or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision	[⊠] Noi	ne	
	of study			Click the tab key to add additional rows.
	materials, medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 month	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] No	ne	

3	Royalties or licenses	None
4	Consulting fees	None     Non
5	Payment or honoraria for	None     Non
	lectures,	
	presentations,	
	speakers bureaus,	
	manuscript writing or educational	
	events	
6	Payment for expert testimony	
7	Support for attending	⊠ None
	meetings and/or	
	travel	
8	Patents planned, issued or	
	pending	
9	Participation on a Data Safety	⊠ None
	Monitoring	
	Board or	
	Advisory Board	
10	Leadership or fiduciary role in	
	other board,	
	society, committee or	
	committee or	

	advocacy group, paid or unpaid	
11	Stock or stock options	[⊠] None
12	Receipt of equipment,	[⊠]   None
	materials, drugs,	
	medical writing,	
	gifts or other	
	services	
13	Other financial or non-financial	⊠  None
	interests	
Please place an "X" next to the following statement to indicate your agreement:		
$\boxtimes$	I certify that I have	answered every question and have not altered the wording of any of the questions on this form.

Date:	4/11/2023
Your Name:	Gal Markel
Manuscript Title:	Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis of Redaction Rates and the Anticipated RAPTURE
Manuscript Number (if known):	BMJ-2023-077329

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
	All support for the present	□ None	
	manuscript (e.g.,	Samueli Foundation	Institutional
	funding, provision of study		Click the tab key to add additional rows.
	materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	Samueli Foundation	Institutional
3	Royalties or licenses	□ None	
		Purple Biotech	Personal
		4c Biomed	Personal
4	Consulting fees	None	
		Beyond Air Cancer Starget Biopharma	Personal Personal
		Starget Biopharma	i cisoriai
5	Payment or honoraria for	□ None	
	lectures, presentations,	MSD BMS	Personal Personal
	speakers	Novartis	Personal
	bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	

7	Support for attending	□ None		
	meetings and/or	Sanofi		
	travel			
8	Patents planned, issued or	[⊠] None		
	pending			
	F0			
9	Participation on a Data Safety	□ None		
	Monitoring	MSD (melanoma regional advisory board)	Personal	
	Board or	Nucleai SAB	Personal	
	Advisory Board	Biond Biologics SAB	Personal	
10	Leadership or fiduciary role in	[□] None		
	other board,	Melanoma patient advocacy group in Israel	Board member, Unpaid	
	society,			
	committee or			
	advocacy group, paid or unpaid			
11	Stock or stock options	None		
		Biond Biologics	Personal (stocks)	
		4c Biomed	Personal (stocks)	
		Nucleai Purple Biotech	Personal (options) Personal (stocks)	
		Ригріе віосесті	Personal (Stocks)	
12	Receipt of equipment,	[⊠] None		
	materials, drugs,			
	medical writing,			
	gifts or other			
	services			
13	Other financial or non-financial	⊠ None		
	interests			
	IIICICSIS			
Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Amir Massarweh  Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis	
of Redaction Rates and the Anticipated RAPTURE	
BMJ-2023-077329	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Click the tab key to add additional rows.
		Time frame: past 36 mont	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	$\boxtimes$	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		None	
6	Payment for expert testimony		None	
7	attending		None	
	meetings and/or travel			
	Havei			
8	Patents planned, issued or		None	
	pending			
9	Participation on a Data Safety		None	
	Monitoring			
	Board or Advisory Board			
	ravisory Board			
10	fiduciary role in		None	
	other board, society,			
	committee or			
	advocacy group, paid or unpaid			

11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None    Output   Outp
13	Other financial or non-financial interests	None    Output
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	4/11/2023
Your Name:	David Bomze
Manuscript Title:	Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis of Redaction Rates and the Anticipated RAPTURE
Manuscript Number (if known):	BMJ-2023-077329

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time frame: Since the initial planning of the work				

manuscript (e.g., bunding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Time frame: past 36 months  Time frame: past 36 months  None  None		All support for the present		None	
of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Time frame: past 36 months  7 Grants or contracts from any entity (if not indicated in item #1 above).  8 Royalties or licenses  8 None  9 None  1 Consulting fees  9 None  1 None  2 None  3 Royalties or licenses  4 Consulting fees  9 None  1 None  1 None  1 None  2 None  4 None  5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for None					
materials, medical writing, article processing charges, etc.) No time limit for this item.  Time frame: past 36 months    Some   None					Click the tab key to add additional rows
medical writing, article processing charges, etc.) No time limit for this item.  Time frame: past 36 months  Time frame: past 36 months  None			J		click the tab key to add additional rows.
Charges, etc.  No time limit for this item.   Time frame: past 36 months		medical writing,			
No time limit for this item.  Time frame: past 36 months  Time frame: past 36 months  Solution of contracts from any entity (if not indicated in item #1 above).  None					
this item.  Time frame: past 36 months  Z Grants or contracts from any entity (if not indicated in item #1 above).  None  None  None  Consulting fees  None					
Sample of contracts from any entity (if not indicated in item #1 above).					
Sample of contracts from any entity (if not indicated in item #1 above).				Time frame: past 36 months	
contracts from any entity (if not indicated in item #1 above).  3 Royalties or licenses  A Consulting fees  None	2	Crants or			
indicated in item #1 above).  Royalties or licenses  None  Consulting fees  None  Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None  None  None	2			None	
#1 above).  Royalties or licenses  None  Consulting fees  None  None  Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None  None  None  None  None  None					
Royalties or licenses    None			-		
licenses    Consulting fees		#1 above).			
licenses    Consulting fees	2	Povalties or		None	
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None	3			None	
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None					
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None					
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None					
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  None  None					
honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for	4	Consulting fees	$\boxtimes$	None	
honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for					
honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for					
honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for					
honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for					
lectures, presentations, speakers bureaus, manuscript writing or educational events	5		$\boxtimes$	None	
speakers bureaus, manuscript writing or educational events  None  None					
bureaus, manuscript writing or educational events  None  None					
manuscript writing or educational events  None  Manuscript Writing or education al events					
educational events  6 Payment for  None  None					
events  6 Payment for  None  None					
6 Payment for 🗵 None					
			[_ 1		
	6			None	

7	Support for attending meetings and/or	None	
	travel		
8	Patents planned, issued or pending	None  None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None    Output   Outp	
11	Stock or stock options	None  None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None  None	
13	Other financial or non-financial interests	None  None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	4/11/2023
Your Name:	Ghulam Rehman Mohyuddin
Manuscript Title:	Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis of Redaction Rates and the Anticipated RAPTURE
Manuscript Number (if known):	BMJ-2023-077329
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial pla	nning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None  None	Click the tab key to add additional rows.
		Time frame: past 36	months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

4	Consulting fees	$\boxtimes$	None	
5	Payment or honoraria for		None	
	lectures, presentations,			
	speakers			
	bureaus,			
	manuscript			
	writing or educational			
	events			
			A1 -	
6	Payment for expert testimony	[oxtimes]	None	
7	Support for attending		None	
	meetings and/or			
	travel			
		r 1		
8	Patents planned,	[oxtimes]	None	
	issued or			
	pending			
		[_ 1		
9	Participation on a Data Safety		None	
	Monitoring			
	Board or			
	Advisory Board			
10	Leadership or		None	
10	fiduciary role in		HOHE	
	other board,			
	society,			
	committee or			
	advocacy group, paid or unpaid			

11	Stock or stock options	No	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠  No	one	
13	Other financial or non-financial interests	GRM h	as received royalties for writing shupMD	
Plea [⊠]	•		llowing statement to indicate your agreem I every question and have not altered the w	
			ICMJE DISCLOSURE FO	DRM
Date	e:		4/11/2023	
	r Name:		Nir Balaban	
Mar	nuscript Title:		Projecting When Complete Redaction (RAF of Redaction Rates and the Anticipated RAF)	PTURE) of Clinical Trial Protocols Occurs: An Analysis PTURE
Mar	nuscript Number (if	known):	BMJ-2023-077329	
cont affe	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
epic	The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.			
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			vithout time limit. For all other items, the time
			Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning of	of the work

	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None  Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None  None
3	Royalties or licenses	None None
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None  None

7	Support for attending meetings and/or	None	
	travel		
8	Patents planned, issued or pending	None  None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None    Output   Outp	
11	Stock or stock options	None  None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None  None	
13	Other financial or non-financial interests	None  None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	4/11/2023		
Your Name:	Daniel Goldstein		
Manuscript Title:	Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis of Redaction Rates and the Anticipated RAPTURE		
Manuscript Number (if known):	BMJ-2023-077329		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month:	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	MSD Janssen	Institutional Research Funding Institutional Research Funding Institutional Research Funding
3	Royalties or licenses	None None □	

4	Consulting fees	$\boxtimes$	None	
5	Payment or honoraria for		None	
	lectures, presentations,			
	speakers			
	bureaus,			
	manuscript			
	writing or educational			
	events			
			A1 -	
6	Payment for expert testimony	[oxtimes]	None	
7	Support for attending		None	
	meetings and/or			
	travel			
		r 1		
8	Patents planned,	[oxtimes]	None	
	issued or			
	pending			
		[_ 1		
9	Participation on a Data Safety		None	
	Monitoring			
	Board or			
	Advisory Board			
10	Leadership or		None	
10	fiduciary role in		HOHE	
	other board,			
	society,			
	committee or			
	advocacy group, paid or unpaid			

11	Stock or stock options	⊠ None				
	ορτιοτίσ					
12	Receipt of equipment, materials, drugs, medical writing,	□ None				
	gifts or other services					
13 Other financial or non-financial     None						
	interests					
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.						
ICMJE DISCLOSURE FORM						
Date:		4/11/2023				
Your Name:		Tomer Meirson				
Ma	nuscript Title:	Projecting When Complete Redaction (RAPTURE) of Clinical Trial Protocols Occurs: An Analysis of Redaction Rates and the Anticipated RAPTURE				
Ma	nuscript Number (if l	known): BMJ-2023-077329				
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.						
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.						
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initial planning of the work				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	
4	Consulting fees	Purple Biotechs	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
8	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None		
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				